Nuvation Bio Inc. has disclosed drug conjugates comprising a nuclear receptor-targeting moiety covalently linked to a poly(ADP-ribose) polymerase 1 (PARP1) and/or PARP2 inhibitor though a linker. They are reported to be potentially useful for the treatment of cancer.